Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2091]

Positive results in phase II study of copanlisib treating NHL and CLL

Dr George Follows - Cambridge University Hospitals NHS Foundation Trust...

Positive results in phase II study of copanlisib treating NHL and CLL ( Dr George Follows - Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK )

Dual mTOR inhibition effective in reducing tumour load in CLL

Dr Emilio Cosimo - University of Glasgow, Glasgow, UK

Dual mTOR inhibition effective in reducing tumour load in CLL ( Dr Emilio Cosimo - University of Glasgow, Glasgow, UK )

Putting the patient at the centre of cancer-associated thrombosis treatment...

Dr Simon Noble - Cardiff University, Cardiff, UK

Putting the patient at the centre of cancer-associated thrombosis treatment decisions ( Dr Simon Noble - Cardiff University, Cardiff, UK )

Pembrolizumab showed clinical benefit in malignant pleural mesothelioma

Dr Evan Alley - University of Pennsylvania, Philadelphia, USA

Pembrolizumab showed clinical benefit in malignant pleural mesothelioma ( Dr Evan Alley - University of Pennsylvania, Philadelphia, USA )

Chk1 inhibition combined with standard dose gemcitabine may be safe and...

Dr Jeffrey Infante - Sarah Cannon Research Institute, Nashville, USA

Chk1 inhibition combined with standard dose gemcitabine may be safe and effective ( Dr Jeffrey Infante - Sarah Cannon Research Institute, Nashville, USA )

Updated results on phase III CLL trial shows 90% response rate using ibrutinib

Dr Claire Dearden - Royal Marsden Hospital, London, UK

Updated results on phase III CLL trial shows 90% response rate using ibrutinib ( Dr Claire Dearden - Royal Marsden Hospital, London, UK )

BRAF 'behind the scenes' in melanoma: A scientific story of discovery

Prof Richard Marais - Cancer Research UK Manchester Institute, Manchester, UK

BRAF 'behind the scenes' in melanoma: A scientific story of discovery ( Prof Richard Marais - Cancer Research UK Manchester Institute, Manchester, UK )

Connecting science, practice and patient outcomes: Use of BRAF inhibitors for...

Dr Bart Neyns - Universitair Ziekenhuis Brussels, Brussels, Belgium

Connecting science, practice and patient outcomes: Use of BRAF inhibitors for treating metastatic melanoma in clinical practice ( Dr Bart Neyns - Universitair Ziekenhuis Brussels, Brussels, Belgium )

Response and resistance with BRAF inhibitors: Mechanisms, markers and...

Dr Keith Flaherty - Massachusetts General Hospital Cancer Centre, Boston, USA

Response and resistance with BRAF inhibitors: Mechanisms, markers and unanswered questions ( Dr Keith Flaherty - Massachusetts General Hospital Cancer Centre, Boston, USA )

DNA repair inhibitors to overcome drug resistance

Dr Ruth Plummer - Newcastle University, Newcastle, UK

DNA repair inhibitors to overcome drug resistance ( Dr Ruth Plummer - Newcastle University, Newcastle, UK )

Refining the role of PARP inhibitors in targeted anticancer therapy

Prof Yves Pommier - National Cancer Institute, Bethesda, USA

Refining the role of PARP inhibitors in targeted anticancer therapy ( Prof Yves Pommier - National Cancer Institute, Bethesda, USA )

Developments in immunotherapy

Prof Lillian Siu - University Health Network, Toronto, Canada

Developments in immunotherapy ( Prof Lillian Siu - University Health Network, Toronto, Canada )

More from ecancer